Loading
A phase 2 trial of APG-157 run by Elizabeth J Franzmann, now recruiting.
A Proof of Concept Trial Investigating Safety and Efficacy of APG-157 in Oral Dysplasia is a phase 2 interventional study registered as NCT05865028 by Elizabeth J Franzmann, with 32 participants planned, started 2023-05-24. Conditions recorded: Oropharyngeal Dysplasia, Oral Cavity Dysplasia and Oral Carcinoma in Situ. Interventions recorded: APG-157.
Shares Aveta Biomics, APG-157, Oropharyngeal cancer (tonsil and base of tongue), Oral cavity cancer (mouth and tongue) and the tag pipeline.
Shares Aveta Biomics, APG-157, Oropharyngeal cancer (tonsil and base of tongue), Oral cavity cancer (mouth and tongue) and the tag pipeline.
Shares Aveta Biomics, APG-157 and the tag pipeline.
Shares Oropharyngeal cancer (tonsil and base of tongue), Oral cavity cancer (mouth and tongue) and the tag pipeline.
Shares Oropharyngeal cancer (tonsil and base of tongue) and the tag pipeline.
Shares Oral cavity cancer (mouth and tongue) and the tag pipeline.
Shares Oral cavity cancer (mouth and tongue) and the tag pipeline.
Shares Oral cavity cancer (mouth and tongue) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/